Replimune Group, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Sushil Patel
- Full Time Employees
- 465
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 500 Unicorn Park Drive Woburn MA United States of America 01801
- IPO Date
- Jul 20, 2018
- CIK
- 0001737953
- Website
- replimune.com
- Similar Companies
- Business
- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company, develops oncolytic immunotherapies based on its proprietary RPx platform, which utilizes an engineered herpes simplex virus 1 (HSV-1) backbone to selectively replicate in and destroy tumor cells while stimulating systemic anti-tumor immune responses; its lead product candidate RP1 (vusolimogene oderparepvec) expresses GALV-GP R(-) and human GM-CSF for treating solid tumors including advanced melanoma; RP2 incorporates an anti-CTLA-4 antibody-like protein to enhance T-cell activation; and RP3 expresses multiple immune-activating transgenes including anti-CTLA-4 and immune stimulatory proteins to further potentiate immune responses against cancer. Founded in 2015 and headquartered in Woburn, Massachusetts, the company conducts operations primarily in the United States and the United Kingdom, targeting patients with solid tumors such as melanoma, skin, and other cancers through clinical-stage programs often in combination with checkpoint inhibitors like nivolumab (Opdivo). In recent developments, Replimune submitted a biologics license application (BLA) to the U.S. FDA for RP1 plus nivolumab in advanced melanoma post-anti-PD1 therapy, which received priority review before a complete response letter (CRL) in July 2025; the company resubmitted the BLA in October 2025 with additional data and analyses addressing FDA feedback, earning acceptance and a PDUFA target action date of April 10, 2026; additionally, it announced a proposed $125 million public offering of common stock in November 2024, with a 30-day underwriter option for $18.75 million more, to fund clinical development and operations.
Company News
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in Replimune Group, Inc. Lawsuit - REPL
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th
Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky
REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact SueWallSt
Portnoy Law Firm Announces Class Action on Behalf of Replimune Group, Inc. Investors
Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
REPL Investor Alert: Replimune Group, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
REPL Deadline Alert: SueWallSt Reminds Replimune Group, Inc. (REPL) Investors of Securities Class Action Deadline on October 5, 2026
REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines – REPL